Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)

Introduction and background: Head and neck squamous cell carcinoma (HNSCC) has been increasingly recognized as an immune suppressive malignancy. The efficacy of immune checkpoint inhibitors (ICI’s) in the context of recurrent/metastatic (R/M) setting anticipates the possible integration of immunothe...

Полное описание

Библиографические подробности

Главные авторы:	Pierluigi Bonomo, Isacco Desideri, Mauro Loi, Monica Mangoni, Mariangela Sottili, Livia Marrazzo, Cinzia Talamonti, Daniela Greto, Stefania Pallotta, Lorenzo Livi
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2018-02-01
Серии:	Clinical and Translational Radiation Oncology
Предметы:	Radiotherapy Head and neck cancer Cetuximab Durvalumab Immunotherapy
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2405630817301027
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!